nach oben

Erschienen in:

16.04.2021 | Special Section: HCC treatment

Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation. Part two: noncurative intention

verfasst von: Joseph H. Yacoub, David Mauro, Andrew Moon, Aiwu R. He, Mustafa R. Bashir, Christine C. Hsu, Thomas M. Fishbein, Lauren M. B. Burke

Erschienen in: Abdominal Radiology | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Abstract

Locoregional therapies can be offered to hepatocellular carcinoma patients as a bridge to transplant, to downstage disease burden for transplant eligibility, or for disease control to prolong survival. Systemic therapies also play a large role in HCC treatment, occasionally in conjunction with other methods. This manuscript reviews the various treatment options for HCC with a historically noncurative intent.

Brown KT, Do RK, Gonen M, et al. Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol. 2016;34(17):2046–2053. https://doi.org/10.1200/JCO.2015.64.0821.CrossRefPubMedPubMedCentral

Raoul J-L, Sangro B, Forner A, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev. 2011;37(3):212–220. https://doi.org/10.1016/j.ctrv.2010.07.006.CrossRefPubMed

Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37(2):429–442. https://doi.org/10.1053/jhep.2003.50047.CrossRefPubMed

Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev. 2011;(3)https://doi.org/10.1002/14651858.cd004787.pub2.

Cammà C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of randomized controlled trials. Radiology. 2002;224(1):47–54. https://doi.org/10.1148/radiol.2241011262.CrossRefPubMed

Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30(1):6–25. https://doi.org/10.1007/s00270-006-0062-3.CrossRefPubMed

Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology. Hepatology; 2011. p. 1020–1022https://doi.org/10.1002/hep.24199.

Llovet JM, Ducreux M, Lencioni R, et al. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943. https://doi.org/10.1016/j.jhep.2011.12.001.CrossRef

Malagari K, Pomoni M, Kelekis A, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2010;33(3):541–551. https://doi.org/10.1007/s00270-009-9750-0.CrossRefPubMed

10.

Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: Results of the PRECISION v study. Cardiovasc Intervent Radiol. 2010;33(1):41–52. https://doi.org/10.1007/s00270-009-9711-7.CrossRefPubMed

11.

Golfieri R, Giampalma E, Renzulli M, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111(2):255–264. https://doi.org/10.1038/bjc.2014.199.CrossRefPubMedPubMedCentral

12.

Cheng AL, Amarapurkar D, Chao Y, et al. Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel. Liver Int. 2014;34(2):174–183. https://doi.org/10.1111/liv.12314.CrossRefPubMed

13.

Mähringer-Kunz A, Kloeckner R, Pitton MB, et al. Validation of the Risk Prediction Models STATE-Score and START-Strategy to Guide TACE Treatment in Patients with Hepatocellular Carcinoma. Cardiovasc Intervent Radiol. 2017;40(7):1017–1025. https://doi.org/10.1007/s00270-017-1606-4.CrossRefPubMed

14.

Yuan-Dong S, Hao Z, Hui-Rong X, et al. Combination therapy: Meta-analysis of the effects of TACE and cryoablation on hepatocellular carcinoma. Med (United States). 2019;98(49)https://doi.org/10.1097/MD.0000000000018030.

15.

Li L, Tian J, Liu P, Wang X, Zhu Z. Transarterial chemoembolization combination therapy vs monotherapy in unresectable hepatocellular carcinoma: A meta-analysis. Tumori. 2016;102(3):301–310. https://doi.org/10.5301/tj.5000491.CrossRef

16.

Chen QF, Jia ZY, Yang ZQ, Fan WL, Shi H Bin. Transarterial Chemoembolization Monotherapy Versus Combined Transarterial Chemoembolization–Microwave Ablation Therapy for Hepatocellular Carcinoma Tumors ≤5 cm: A Propensity Analysis at a Single Center. Cardiovasc Intervent Radiol. 2017;40(11):1748–1755. https://doi.org/10.1007/s00270-017-1736-8.

17.

Xu LF, Sun HL, Chen YT, et al. Large primary hepatocellular carcinoma: Transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy. J Gastroenterol Hepatol. 2013;28(3):456–463. https://doi.org/10.1111/jgh.12088.CrossRefPubMed

18.

Sacco R, Conte C, Tumino E, et al. Transarterial radioembolization for hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;Volume 3:25–29. https://doi.org/10.2147/jhc.s50359.CrossRefPubMedPubMedCentral

19.

Tong AKT, Kao YH, Too CW, Chin KFW, Ng DCE, Chow PKH. Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry. Br J Radiol. 2016;89(1062):20150943. https://doi.org/10.1259/bjr.20150943.CrossRefPubMedPubMedCentral

20.

Kim H-C. Radioembolization for the treatment of hepatocellular carcinoma. Clin Mol Hepatol. 2017;23(2):109–114. https://doi.org/10.3350/cmh.2017.0004.CrossRefPubMedPubMedCentral

21.

Ward TJ, Tamrazi A, Lam MGEH, et al. Management of High Hepatopulmonary Shunting in Patients Undergoing Hepatic Radioembolization. J Vasc Interv Radiol. 2015;26(12):1751–1760. https://doi.org/10.1016/j.jvir.2015.08.027.CrossRefPubMed

22.

Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes. Gastroenterology. 2010;138(1):52–64. https://doi.org/10.1053/j.gastro.2009.09.006.CrossRefPubMed

23.

Hilgard P, Hamami M, Fouly A El, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology. 2010;52(5):1741–1749. https://doi.org/10.1002/hep.23944.CrossRefPubMed

24.

Sangro B, Carpanese L, Cianni R, et al. Survival after Yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation. Hepatology. 2011;54(3):868–878. https://doi.org/10.1002/hep.24451.CrossRefPubMed

25.

Salem R, Gordon AC, Mouli S, et al. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;151(6):1155-1163.e2. https://doi.org/10.1053/j.gastro.2016.08.029.CrossRefPubMed

26.

Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140(2):497-507.e2. https://doi.org/10.1053/j.gastro.2010.10.049.CrossRefPubMed

27.

Lewandowski RJ, Gabr A, Abouchaleh N, et al. Radiation Segmentectomy: Potential Curative Therapy for Early Hepatocellular Carcinoma. Radiology. 2018;287(3):1050–1058. https://doi.org/10.1148/radiol.2018171768.CrossRefPubMed

28.

Elsayed M, Ermentrout RM, Sethi I, et al. Incidence of Radioembolization-Induced Liver Disease and Liver Toxicity Following Repeat 90Y-Radioembolization: Outcomes at a Large Tertiary Care Center. Clin Nucl Med. 2020;45(2):100–104. https://doi.org/10.1097/RLU.0000000000002828.CrossRefPubMed

29.

Miften M, Vinogradskiy Y, Moiseenko V, et al. Radiation Dose-Volume Effects for Liver SBRT. Int J Radiat Oncol Biol Phys. 2018;https://doi.org/10.1016/j.ijrobp.2017.12.290.CrossRefPubMedPubMedCentral

30.

Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–750. https://doi.org/10.1002/hep.29913.CrossRefPubMed

31.

Benson AB, D’Angelica MI, Abbott DE, et al. Guidelines Insights: Hepatobiliary Cancers, Version 2.2019. J Natl Compr Cancer Netw. 2019;17(4):302–310. https://doi.org/10.6004/jnccn.2019.0019.

32.

Wahl DR, Stenmark MH, Tao Y, et al. Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma. J Clin Oncol. 2016;34(5):452–459. https://doi.org/10.1200/JCO.2015.61.4925.CrossRefPubMed

33.

Kim N, Kim HJ, Won JY, et al. Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma. Radiother Oncol. 2019;131:81–87. https://doi.org/10.1016/j.radonc.2018.12.013.CrossRefPubMed

34.

Pan CC, Kavanagh BD, Dawson LA, et al. Radiation-Associated Liver Injury. Int J Radiat Oncol Biol Phys. 2010;76(3 SUPPL.)https://doi.org/10.1016/j.ijrobp.2009.06.092.

35.

Schefter TE, Rusthoven KE, Kavanagh BD, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27(10):1572–1578. https://doi.org/10.1200/JCO.2008.19.6329.CrossRefPubMed

36.

Goodman KA, Wiegner EA, Maturen KE, et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys. 2010;78(2):486–493. https://doi.org/10.1016/j.ijrobp.2009.08.020.CrossRefPubMed

37.

Lee MT, Kim JJ, Dinniwell R, et al. Phase i study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009;27(10):1585–1591. https://doi.org/10.1200/JCO.2008.20.0600.CrossRefPubMed

38.

Bujold A, Massey CA, Kim JJ, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013;31(13):1631–1639. https://doi.org/10.1200/JCO.2012.44.1659.CrossRefPubMed

39.

Andolino DL, Johnson CS, Maluccio M, et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2011;81(4)https://doi.org/10.1016/j.ijrobp.2011.04.011.

40.

Kang J-K, Kim M-S, Cho CK, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer. 2012;118(21):5424–5431. https://doi.org/10.1002/cncr.27533.CrossRefPubMed

41.

Bae SH, Kim MS, Cho CK, Kim KB, Han CJ, Kim YH. Feasibility and efficacy of stereotactic ablative radiotherapy for: Barcelona clinic liver cancer-C stage hepatocellular carcinoma. J Korean Med Sci. 2013;28(2):213–219. https://doi.org/10.3346/jkms.2013.28.2.213.CrossRefPubMedPubMedCentral

42.

Barney BM, Olivier KR, Miller RC, Haddock MG. Clinical outcomes and toxicity using Stereotactic Body Radiotherapy (SBRT) for advanced cholangiocarcinoma. Radiat Oncol. 2012;7(1)https://doi.org/10.1186/1748-717X-7-67.

43.

Huang WY, Jen YM, Lee MS, et al. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2012;84(2):355–361. https://doi.org/10.1016/j.ijrobp.2011.11.058.CrossRefPubMed

44.

Cárdenes HR, Price TR, Perkins SM, et al. Phase i feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol. 2010;12(3):218–225. https://doi.org/10.1007/s12094-010-0492-x.CrossRefPubMed

45.

Kim JW, Seong J, Lee IJ, Woo JY, Han KH. Phase I dose-escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma. Oncotarget. 2016;7(26):40756–40766. https://doi.org/10.18632/oncotarget.9450.CrossRefPubMedPubMedCentral

46.

Moon DH, Wang AZ, Tepper JE. A prospective study of the safety and efficacy of liver stereotactic body radiotherapy in patients with and without prior liver-directed therapy. Radiother Oncol. 2018;126(3):527–533. https://doi.org/10.1016/j.radonc.2018.01.004.CrossRefPubMed

47.

Feng M, Suresh K, Schipper MJ, et al. Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage a phase 2 clinical trial. JAMA Oncol. 2018;4(1):40–47. https://doi.org/10.1001/jamaoncol.2017.2303.CrossRefPubMed

48.

Hara K, Takeda A, Tsurugai Y, et al. Radiotherapy for Hepatocellular Carcinoma Results in Comparable Survival to Radiofrequency Ablation: A Propensity Score Analysis. Hepatology. 2019;69(6):2533–2545. https://doi.org/10.1002/hep.30591.CrossRefPubMed

49.

Sapisochin G, Barry A, Doherty M, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol. 2017;67(1):92–99. https://doi.org/10.1016/j.jhep.2017.02.022.

50.

Bush DA, Smith JC, Slater JD, et al. Randomized Clinical Trial Comparing Proton Beam Radiation Therapy with Transarterial Chemoembolization for Hepatocellular Carcinoma: Results of an Interim Analysis. Int J Radiat Oncol Biol Phys. 2016;95(1):477–482. https://doi.org/10.1016/j.ijrobp.2016.02.027.CrossRefPubMed

51.

Huang Y, Chen SW, Fan CC, Ting LL, Kuo CC, Chiou JF. Clinical parameters for predicting radiation-induced liver disease after intrahepatic reirradiation for hepatocellular carcinoma. Radiat Oncol. 2016;11(1)https://doi.org/10.1186/s13014-016-0663-1.

52.

Seol SW, Yu J Il, Park HC, et al. Treatment outcome of hepatic re-irradiation in patients with hepatocellular carcinoma. Radiat Oncol J. 2015;33(4):276–283. https://doi.org/10.3857/roj.2015.33.4.276.

53.

McDuff SGR, Remillard KA, Zheng H, et al. Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis. Pract Radiat Oncol. 2018;8(6):414–421. https://doi.org/10.1016/j.prro.2018.04.012.CrossRefPubMed

54.

Gkika E, Strouthos I, Kirste S, et al. Repeated SBRT for in- and out-of-field recurrences in the liver. Strahlentherapie und Onkol. 2019;195(3):246–253. https://doi.org/10.1007/s00066-018-1385-0.CrossRef

55.

Pinter M, Peck-Radosavljevic M. Review article: systemic treatment of hepatocellular carcinoma. Aliment Pharmacol Ther. 2018;48(6):598–609. https://doi.org/10.1111/apt.14913.CrossRefPubMedPubMedCentral

56.

Mody K, Abou-Alfa GK. Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape. Curr Treat Options Oncol. 2019;20(1):3. https://doi.org/10.1007/s11864-019-0601-1.CrossRefPubMed

57.

Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in Advanced Hepatocellular Carcinoma. N Engl J Med. 2008;359(4):378–390. https://doi.org/10.1056/NEJMoa0708857.CrossRefPubMed

58.

Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. https://doi.org/10.1016/S1470-2045(08)70285-7.CrossRefPubMed

59.

Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. https://doi.org/10.1016/S0140-6736(18)30207-1.CrossRefPubMed

60.

Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66. https://doi.org/10.1016/S0140-6736(16)32453-9.CrossRefPubMed

61.

Abou-Alfa GK, Meyer T, Cheng A-L, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018;379(1):54–63. https://doi.org/10.1056/NEJMoa1717002.CrossRefPubMedPubMedCentral

62.

El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502. https://doi.org/10.1016/S0140-6736(17)31046-2.CrossRefPubMedPubMedCentral

63.

Yau T, Park JW, Finn RS, et al. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2019;30:v874–v875. https://doi.org/10.1093/annonc/mdz394.029.CrossRef

64.

Finn RS, Ryoo B-Y, Merle P, et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2020;38(3):193–202. https://doi.org/10.1200/JCO.19.01307.CrossRefPubMed

65.

Yau T, Kang Y-K, Kim T-Y, et al. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. J Clin Oncol. 2019;37(15_suppl):4012–4012. https://doi.org/10.1200/jco.2019.37.15_suppl.4012.

66.

FDA grants accelerated approval to nivolumab and ipilimumab combination for hepatocellular carcinoma | FDA. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-nivolumab-and-ipilimumab-combination-hepatocellular-carcinoma. Accessed August 15, 2020.

67.

Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894–1905. https://doi.org/10.1056/NEJMoa1915745.CrossRefPubMed

68.

Zhu AX, Kang Y-K, Yen C-J, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282–296. https://doi.org/10.1016/S1470-2045(18)30937-9.CrossRefPubMed

69.

FDA approves ramucirumab for hepatocellular carcinoma | FDA. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ramucirumab-hepatocellular-carcinoma. Accessed August 15, 2020.

70.

FDA approves atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma | FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-atezolizumab-plus-bevacizumab-unresectable-hepatocellular-carcinoma. Accessed August 15, 2020.

71.

Kelley RK. Atezolizumab plus Bevacizumab — A Landmark in Liver Cancer. N Engl J Med. 2020;382(20):1953–1955. https://doi.org/10.1056/NEJMe2004851.CrossRefPubMed

72.

Kudo M. Systemic Therapy for Hepatocellular Carcinoma: Latest Advances. Cancers (Basel). 2018;10(11):412. https://doi.org/10.3390/cancers10110412.CrossRefPubMedCentral

73.

Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. https://doi.org/10.1002/hep.29086.CrossRefPubMed

74.

Kudo M, Ueshima K, Ikeda M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2019;Online ahehttps://doi.org/10.1136/gutjnl-2019-318934.

75.

Chow PKH, Gandhi M, Tan S-B, et al. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncol. 2018;36(19):1913–1921. https://doi.org/10.1200/JCO.2017.76.0892.CrossRefPubMed

76.

Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624–1636. https://doi.org/10.1016/S1470-2045(17)30683-6.CrossRefPubMed

77.

Sposito C, Mazzaferro V. The SIRveNIB and SARAH trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future. Hepatobiliary Surg Nutr. 2018;7(6):487–489. https://doi.org/10.21037/hbsn.2018.10.06.

Titel: Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation. Part two: noncurative intention
verfasst von: Joseph H. Yacoub
David Mauro
Andrew Moon
Aiwu R. He
Mustafa R. Bashir
Christine C. Hsu
Thomas M. Fishbein
Lauren M. B. Burke
Publikationsdatum: 16.04.2021
Verlag: Springer US
Erschienen in: Abdominal Radiology / Ausgabe 8/2021
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI: https://doi.org/10.1007/s00261-021-03074-z

Neu im Fachgebiet Radiologie

08.04.2024 | Andrologie | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation. Part two: noncurative intention

Abstract

Neu im Fachgebiet Radiologie

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Quantitative Angiografie könnte IVUS-Alternative darstellen

Die Ganz-Genom-Sequenzierung startet

Update Radiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2021

The absolute tumor-capsule contact length in the diagnosis of extraprostatic extension of prostate cancer

Performance of imaging interpretation, intra- and inter-reader agreement for diagnosis of pelvic endometriosis: comparison between an abbreviated and full MRI protocol

Impact of 18F-FDG PET/MR based tumor delineation in radiotherapy planning for cholangiocarcinoma

Cross-sectional imaging features of unusual adrenal lesions: a radiopathological correlation

Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation—part one: curative intention

MRI-Based Radiomics: Nomograms predicting the short-term response after transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma patients with diameter less than 5 cm

Neu im Fachgebiet Radiologie

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Quantitative Angiografie könnte IVUS-Alternative darstellen

Die Ganz-Genom-Sequenzierung startet

Update Radiologie